PR Newswire Clinical TrialsOriginal article
New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia
Data ReadoutpositiveTryngolzaPositive
AI Analysis
Summary
Sobi announced positive Phase 3 data for Tryngolza (olezarsen) showing 85% reduction in acute pancreatitis risk and 66% triglyceride reduction in patients with severe hypertriglyceridemia from the CORE and CORE2 trials.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
85% reduction in acute pancreatitis relative risk, 66% triglyceride reduction
Importance:7/10
Sentiment:
0.85
Phase 3Data ReadoutPancreatitisHypertriglyceridemiaPositive Results
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on May 26, 2026 2:50 PM